Italian firm brings bacterial conjunctivitis drug to Asia
Italian firm brings bacterial conjunctivitis drug to Asia 18 January 2021 | News NTC014 seeks to provide physicians with rational treatment for moderate to severe bacterial conjunctivitis, a common eye infection
Source credit: Shutterstock
NTC, an international R&D-focused pharmaceutical company based in Italy, and Zhaoke (Hong Kong) Ophthalmology Pharmaceuticals Limited, have fully integrated the ophthalmology platform with a leading foundation in eye care, announced its agreement for an exclusive license and distribution rights to NTC014, an innovative fixed combination of quinolone antibiotic and NSAID eye drops. Zhaoke will commercialise NTC014 in the People s Republic of China , Hong Kong , Macao , Taiwan, ASEAN countries and South Korea .
NTC grants to Zhaoke exclusive license and distribution rights in Asia for NTC014, innovative drug for bacterial conjunctivitis
14/01/2021 - 11:30 ); );
MILAN, Italy and HONG KONG, Jan. 14, 2021 /PRNewswire/ NTC, an international R&D focused pharmaceutical company headquartered in Italy, and Zhaoke (Hong Kong) Ophthalmology Pharmaceuticals Limited, having a fully integrated ophthalmic platform with strong foundation in eyecare, announce today their agreement for exclusive license and distribution rights of NTC014, innovative fixed combination of a quinolone antibiotic and a NSAID in eye drops. Zhaoke will market NTC014 in the People s Republic of China, Hong Kong, Macau, Taiwan, ASEAN countries, and South Korea.
14 gennaio 2021 11:08
Fonte: Adnkronos
#salute-e-benessere
MILAN, Italy and HONG KONG, Jan. 14, 2021 /PRNewswire/ NTC, an international R&D focused pharmaceutical company headquartered in Italy, and Zhaoke (Hong Kong) Ophthalmology Pharmaceuticals Limited, having a fully integrated ophthalmic platform with strong foundation in eyecare, announce today their agreement for exclusive license and distribution rights of NTC014, innovative fixed combination of a quinolone antibiotic and a NSAID in eye drops. Zhaoke will market NTC014 in the People s Republic of China, Hong Kong, Macau, Taiwan, ASEAN countries, and South Korea.
NTC014 aims to provide physicians with a rational treatment for moderate-severe bacterial conjunctivitis, a common eye infection. Actual treatment is mainly based on antibiotics combined/or not with steroids with no clear time window of administration. NTC014 is a first in class eye drop solution combining an antibiotic highly effective on the bacteria most